鲁索利替尼治疗特应性皮炎的安全性、有效性和患者咨询综述。

Q4 Medicine

Skinmed Pub Date : 2023-01-01

Elizabeth Mancuso-Stewart, Jaimie Rodger, Matthew Zirwas

{"title":"鲁索利替尼治疗特应性皮炎的安全性、有效性和患者咨询综述。","authors":"Elizabeth Mancuso-Stewart, Jaimie Rodger, Matthew Zirwas","doi":"","DOIUrl":null,"url":null,"abstract":"Ruxolitinib, a Janus kinase (JAK) inhibitor, has been used orally for over a decade in the treatment of myelofibrosis. The immunosuppressive and anti-inflammatory properties of ruxolitinib have made it an attractive treatment option for several dermatologic conditions, such as atopic dermatitis, psoriasis, alopecia areata, and vitiligo. In October 2021, US Food and Drug Administration approved ruxolitinib as the first topical JAK inhibitor for treating atopic dermatitis. Recent studies have demonstrated its efficacy for both visible manifestations and itch of atopic dermatitis. These results indicate that topical ruxolitinib could be used as a long-term glucocorticoid for treating atopic dermatitis. While more studies are required to compare it to classic topical treatments of atopic dermatitis, topical ruxolitinib has a promising future in the field of dermatology. (SKINmed. 2023;21:40-43).","PeriodicalId":21891,"journal":{"name":"Skinmed","volume":"21 1","pages":"40-43"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Overview of Safety, Efficacy, and Patient Counseling for Ruxolitinib in Treating Atopic Dermatitis.\",\"authors\":\"Elizabeth Mancuso-Stewart, Jaimie Rodger, Matthew Zirwas\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ruxolitinib, a Janus kinase (JAK) inhibitor, has been used orally for over a decade in the treatment of myelofibrosis. The immunosuppressive and anti-inflammatory properties of ruxolitinib have made it an attractive treatment option for several dermatologic conditions, such as atopic dermatitis, psoriasis, alopecia areata, and vitiligo. In October 2021, US Food and Drug Administration approved ruxolitinib as the first topical JAK inhibitor for treating atopic dermatitis. Recent studies have demonstrated its efficacy for both visible manifestations and itch of atopic dermatitis. These results indicate that topical ruxolitinib could be used as a long-term glucocorticoid for treating atopic dermatitis. While more studies are required to compare it to classic topical treatments of atopic dermatitis, topical ruxolitinib has a promising future in the field of dermatology. (SKINmed. 2023;21:40-43).\",\"PeriodicalId\":21891,\"journal\":{\"name\":\"Skinmed\",\"volume\":\"21 1\",\"pages\":\"40-43\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Skinmed\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skinmed","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

Ruxolitinib是一种Janus激酶(JAK)抑制剂，口服治疗骨髓纤维化已有十多年的历史。鲁索利替尼的免疫抑制和抗炎特性使其成为几种皮肤病的有吸引力的治疗选择，如特应性皮炎、牛皮癣、斑秃和白癜风。2021年10月，美国食品和药物管理局批准ruxolitinib作为治疗特应性皮炎的第一个局部JAK抑制剂。最近的研究表明，它对特应性皮炎的可见表现和瘙痒都有疗效。这些结果表明，外用鲁索利替尼可作为治疗特应性皮炎的长期糖皮质激素。虽然需要更多的研究将其与经典的局部治疗特应性皮炎进行比较，但局部ruxolitinib在皮肤病学领域具有广阔的前景。(SKINmed。2023; 21:40-43)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

Overview of Safety, Efficacy, and Patient Counseling for Ruxolitinib in Treating Atopic Dermatitis.

Ruxolitinib, a Janus kinase (JAK) inhibitor, has been used orally for over a decade in the treatment of myelofibrosis. The immunosuppressive and anti-inflammatory properties of ruxolitinib have made it an attractive treatment option for several dermatologic conditions, such as atopic dermatitis, psoriasis, alopecia areata, and vitiligo. In October 2021, US Food and Drug Administration approved ruxolitinib as the first topical JAK inhibitor for treating atopic dermatitis. Recent studies have demonstrated its efficacy for both visible manifestations and itch of atopic dermatitis. These results indicate that topical ruxolitinib could be used as a long-term glucocorticoid for treating atopic dermatitis. While more studies are required to compare it to classic topical treatments of atopic dermatitis, topical ruxolitinib has a promising future in the field of dermatology. (SKINmed. 2023;21:40-43).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Skinmed Medicine-Medicine (all)

CiteScore

0.40

自引率

0.00%

发文量

期刊介绍： SKINmed is a peer-reviewed bimonthly publication circulated to more than 28,000 dermatologists, allergists, internists, pediatricians, and family practitioners with an interest in dermatology and allergy. SKINmed features articles, original papers, and case studies concerning clinical aspects of dermatology, including dermatopathology, diagnostics, occupational dermatology, malignancy/tumors, cosmetic dermatology, endocrine diseases, infestations, infections, and pharmacotherapy.